| Literature DB >> 31864289 |
Fei She1, Yuan Ma2,3,4, Yi Li2,3,4, Lei Li2,3,4, Weixian Xu2,3,4, Hongyan Wang2,3,4, Ming Cui5,6,7.
Abstract
BACKGROUND: The optimal level of heart rate (HR) control in patients with atrial fibrillation (AF) is unknown. To assess the effect of rate control on cardiopulmonary exercise capacity and quality of life (QoL) in permanent AF.Entities:
Keywords: Anaerobic threshold; Heart rate control; Peak metabolic equivalent; Peak oxygen uptake; Permanent atrial fibrillation; Quality of life
Mesh:
Substances:
Year: 2019 PMID: 31864289 PMCID: PMC6925461 DOI: 10.1186/s12872-019-01293-3
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.298
Baseline characteristics of the study patients
| Characteristic | |
|---|---|
| Total population ( | 143 |
| Age (year) | 67.0 ± 9.0 |
| Male ( | 100 (70.0) |
| Smoke ( | 27 (18.9) |
| Duration of AF (month) | 60 (36–108) |
| Hypertension ( | 72 (50.3) |
| Coronary heart disease ( | 21 (14.7) |
| Valvular disease ( | 5 (3.5) |
| Dilated cardiomyopathy ( | 0 (0) |
| Diabetes ( | 20 (14.0) |
| BMI (kg/m2) | 26.4 ± 3.3 |
| Abdominal girth (cm) | 93.4 ± 9.5 |
| Blood pressure (mm Hg) | |
| Systolic | 124.7 ± 17.3 |
| Diastolic | 77.8 ± 10.8 |
| LVEF (%) | 62.4 ± 13.6 |
| NYHA functional class ( | |
| I | 97 (67.8) |
| II | 46 (32.2) |
BMI body mass index, LVEF left ventricular ejection fraction, NYHA New York Heart Association
Primary pharmacological therapy
| Medications | |
|---|---|
| β-Blocker | 82 (57.5) |
| Digoxin | 11 (8) |
| Calcium-channel blocker | 13 (9.2) |
| β-Blocker + calcium-channel-blocker | 30 (20.7) |
| β-Blocker + calcium-channel-blocker + digoxin | 7 (4.6) |
Cardiopulmonary exercise capacity and quality of life with respect to resting HR
| Variable | Resting HR ≤80 bpm ( | Resting HR > 80 bpm ( | |
|---|---|---|---|
| CPET | |||
| VO2peak/kg [mL/(kg·min)] | 21.5 ± 5.3 | 22.1 ± 6.0 | 0.560 |
| MET peak | 6.3 ± 1.6 | 6.0 ± 1.7 | 0.860 |
| VO2AT/kg [mL/(kg·min)] | 20.9 ± 4.9 | 22.3 ± 6.6 | 0.261 |
| SF-36 score | |||
| PCS | 356.2 ± 37.7 | 318.2 ± 51.6 | 0.001 |
| MCS | 359.4 ± 40.5 | 314.9 ± 52.2 | 0.000 |
AT Anaerobic threshold, CPET cardiopulmonary exercise testing, HR heart rate, MCS mental component summary, MET peak peak metabolic equivalent, PCS physical component summary, SF-36 Short-form health survey, VOpeak Peak oxygen uptake
Cardiopulmonary exercise capacity and quality of life with respect to exercise HR
| Variable | Exercise HR ≤110 bpm ( | Exercise HR > 110 bpm ( | |
|---|---|---|---|
| CPET | |||
| VO2peak/kg [mL/(kg·min)] | 21.8 ± 5.3 | 21.7 ± 5.9 | 0.940 |
| MET peak | 6.4 ± 1.6 | 6.2 ± 1.7 | 0.578 |
| VO2AT/kg [mL/(kg·min)] | 21.0 ± 5.4 | 21.6 ± 5.8 | 0.790 |
| SF-36 score | |||
| PCS | 358.0 ± 40.0 | 320.7 ± 48.2 | 0.001 |
| MCS | 362.0 ± 39.7 | 317.4 ± 51.2 | 0.000 |
CPET Cardiopulmonary exercise testing, HR Heart rate, MCS Mental component summary, MET peak Peak metabolic equivalent, PCS Physical component summary, SF-36 short-form health survey, VOpeak peak oxygen uptake
Cardiopulmonary exercise capacity and quality of life with respect to the combination of resting HR and exercise HR
| Variable | Resting HR ≤80 bpm and Exercise HR ≤110 bpm ( | Resting HR > 80 bpm or Exercise HR > 110 bpm ( | |
|---|---|---|---|
| CPET | |||
| VO2peak/kg [mL/(kg·min)] | 22.3 ± 4.7 | 21.5 ± 6.0 | 0.385 |
| METs peak | 6.6 ± 1.4 | 6.0 ± 1.7 | 0.158 |
| VO2AT/kg [mL/(kg·min)] | 21.9 ± 4.7 | 21.2 ± 6.1 | 0.644 |
| SF-36 score | |||
| PCS | 362.1 ± 34.4 | 323.3 ± 49.8 | 0.001 |
| MCS | 367.2 ± 33.7 | 320.4 ± 52.1 | 0.000 |
CPET cardiopulmonary exercise testing, HR heart rate, MCS mental component summary, MET peak peak metabolic equivalent, PCS physical component summary, SF-36 short-form health survey, VOpeak peak oxygen uptake